BrainStorm Cell Therapeutics Inc.
Tel Aviv
425 articles about BrainStorm Cell Therapeutics Inc.
-
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
11/7/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, November 14, 2022.
-
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
11/7/2022
BrainStorm Cell Therapeutics Inc. announced the presentation of a poster with new analyses from NurOwn's placebo-controlled Phase 3 amyotrophic lateral sclerosis trial that account for limitations in the Revised ALS Functional Rating Scale and provide evidence of a clinically meaningful treatment effect.
-
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
10/20/2022
BrainStorm Cell Therapeutics Inc. announced that a scientific abstract titled 'NurOwn Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers' will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held from October 26-28th in Amsterdam, NL.
-
With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem. Venture capitalists would do well to pay attention.
-
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium
10/7/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the presentation of new biomarker analyses supporting the therapeutic benefit of NurOwn® in amyotrophic lateral sclerosis (ALS) at the ongoing 5th Annual ALS ONE Research Symposium.
-
BrainStorm Cell Therapeutics announced the publication of peer-reviewed data from a Phase II trial in progressive multiple sclerosis Thursday showing “preliminary evidence of efficacy.”
-
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
9/15/2022
BrainStorm Cell Therapeutics Inc. announced the peer reviewed publication of data from the Phase 2 trial of NurOwn in progressive multiple sclerosis in Multiple Sclerosis Journal.
-
There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.
-
The FDA provided briefing documents ahead of Amylyx's rare second adcomm for AMX0035, an investigational treatment for ALS. The regulator does not appear to be convinced.
-
BrainStorm Cell Therapeutics said it will submit a Biologics License Application to the FDA for ALS hopeful NurOwn. Additionally, a correction has been made to analyses of the Phase III clinical trial.
-
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
8/15/2022
BrainStorm Cell Therapeutics today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.
-
BrainStorm to Announce Second Quarter 2022 Results and Provide a Corporate Update
8/1/2022
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.
-
BrainStorm Announces Presentations at June 2022 Scientific Conferences
5/31/2022
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announces presentations at forthcoming ALS and MS scientific conferences in June 2022.
-
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
-
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
5/16/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal
5/12/2022
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced two senior management appointments.
-
BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
5/4/2022
BrainStorm Cell Therapeutics Inc. announced the presentation of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA.
-
BrainStorm Announces Upcoming Scientific Conference Presentations - May 03, 2022
5/3/2022
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announces presentations at upcoming scientific conferences in May 2022.
-
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
5/2/2022
BrainStorm Cell Therapeutics Inc. announced that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on May 16, 2022.
-
Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
3/28/2022
Brainstorm Cell Therapeutics announced that the company President and Chief Medical Officer, Ralph Kern, MD MHSc has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.